GSK (LON:GSK) Given “Hold” Rating at Deutsche Bank Aktiengesellschaft

GSK (LON:GSK – Get Free Report)‘s stock had its “hold” rating reiterated by stock analysts at Deutsche Bank Aktiengesellschaft in a research note issued on Tuesday, Digital Look reports. They presently have a GBX 2,000 target price on the stock. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential upside of 11.86% from the stock’s previous close.

Several other brokerages have also recently issued reports on GSK. Berenberg Bank lifted their target price on GSK from GBX 2,000 to GBX 2,200 and gave the company a “hold” rating in a research report on Tuesday, September 15th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 1,975 price objective on shares of GSK in a report on Tuesday, September 8th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a research note on Wednesday, July 29th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of GBX 2,064.38.

Get GSK alerts:

View Our Latest Analysis on GSK

GSK Stock Performance

Shares of GSK stock opened at GBX 1,788 on Tuesday. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. The firm has a fifty day simple moving average of GBX 1,882.52 and a two-hundred day simple moving average of GBX 1,942.08. GSK has a 12 month low of GBX 1,592 and a 12 month high of GBX 2,282. The firm has a market capitalization of £71.65 billion, a PE ratio of 15.18, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK – Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Analysts forecast that GSK will post 175.980975 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Anne Beal acquired 637 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The stock was bought at an average price of GBX 4,985 per share, with a total value of £31,754.45. Also, insider Jonathan Symonds acquired 1,500 shares of the stock in a transaction that occurred on Friday, September 18th. The stock was purchased at an average price of GBX 1,881 per share, for a total transaction of £28,215. Insiders purchased a total of 2,144 shares of company stock worth $6,009,566 in the last ninety days. 0.20% of the stock is currently owned by insiders.

About GSK

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

Featured Stories

• Five stocks we like better than GSK
• Why Concentra’s Quiet Healthcare Business Keeps Winning
• Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
• Alamos Gold’s 1 Million-Ounce Growth Story Is Hiding in Plain Sight
• Everyone in AI Is Quietly Copying Palantir’s Playbook

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.